Ewing Sarcoma - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 210
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E8DFDF3E870EN
Leaflet:

Download PDF Leaflet

Ewing Sarcoma - Pipeline Review, H2 2016
Ewing Sarcoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma – Pipeline Review, H2 2016, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.

Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 7, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 1 and 2 molecules, respectively.Ewing Sarcoma.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Ewing Sarcoma Overview
Therapeutics Development
Pipeline Products for Ewing Sarcoma - Overview
Pipeline Products for Ewing Sarcoma - Comparative Analysis
Ewing Sarcoma - Therapeutics under Development by Companies
Ewing Sarcoma - Therapeutics under Investigation by Universities/Institutes
Ewing Sarcoma - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Ewing Sarcoma - Products under Development by Companies
Ewing Sarcoma - Products under Investigation by Universities/Institutes
Ewing Sarcoma - Companies Involved in Therapeutics Development
Astellas Pharma Inc.
Cebiotex, S.L.
Celgene Corporation
EntreChem, S.L.
Exelixis, Inc.
Gradalis Inc.
Kolltan Pharmaceuticals, Inc.
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
NanoSmart Pharmaceuticals, Inc.
Nanovalent Pharmaceuticals Inc.
NantKwest, Inc.
Novartis AG
Oncomatryx Biopharma, S.L.
Oncternal Therapeutics, Inc.
Pfizer Inc.
Pharma Mar, S.A.
Recombio S.L
Shionogi & Co., Ltd.
Tesaro, Inc.
Ewing Sarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
axitinib - Drug Profile
cabozantinib s-malate - Drug Profile
CEB-01 - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
celyvir - Drug Profile
Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile
EC-8042 - Drug Profile
EC-8105 - Drug Profile
everolimus - Drug Profile
gemogenovatucel-T - Drug Profile
haNK Program - Drug Profile
irinotecan hydrochloride - Drug Profile
KITSG-3227 - Drug Profile
KTN-0182A - Drug Profile
linsitinib - Drug Profile
lurbinectedin - Drug Profile
Monoclonal Antibody Conjugate for Ewing Sarcoma - Drug Profile
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
niraparib - Drug Profile
NV-101 - Drug Profile
OMTX-503 - Drug Profile
OMTX-703 - Drug Profile
ONC-206 - Drug Profile
paclitaxel albumin bound - Drug Profile
pazopanib hydrochloride - Drug Profile
pembrolizumab - Drug Profile
racotumomab - Drug Profile
RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma - Drug Profile
roneparstat - Drug Profile
S-588410 - Drug Profile
Small Molecules for Ewing Sarcoma - Drug Profile
SP-2509 - Drug Profile
SP-2528 - Drug Profile
SP-2577 - Drug Profile
TK-216 - Drug Profile
Vimo-101 - Drug Profile
Ewing Sarcoma - Dormant Projects
Ewing Sarcoma - Discontinued Products
Ewing Sarcoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 208

LIST OF TABLES

Number of Products under Development for Ewing Sarcoma, H2 2016
Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Ewing Sarcoma - Pipeline by Astellas Pharma Inc., H2 2016
Ewing Sarcoma - Pipeline by Cebiotex, S.L., H2 2016
Ewing Sarcoma - Pipeline by Celgene Corporation, H2 2016
Ewing Sarcoma - Pipeline by EntreChem, S.L., H2 2016
Ewing Sarcoma - Pipeline by Exelixis, Inc., H2 2016
Ewing Sarcoma - Pipeline by Gradalis Inc., H2 2016
Ewing Sarcoma - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
Ewing Sarcoma - Pipeline by Merck & Co., Inc., H2 2016
Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
Ewing Sarcoma - Pipeline by NanoSmart Pharmaceuticals, Inc., H2 2016
Ewing Sarcoma - Pipeline by Nanovalent Pharmaceuticals Inc., H2 2016
Ewing Sarcoma - Pipeline by NantKwest, Inc., H2 2016
Ewing Sarcoma - Pipeline by Novartis AG, H2 2016
Ewing Sarcoma - Pipeline by Oncomatryx Biopharma, S.L., H2 2016
Ewing Sarcoma - Pipeline by Oncternal Therapeutics, Inc., H2 2016
Ewing Sarcoma - Pipeline by Pfizer Inc., H2 2016
Ewing Sarcoma - Pipeline by Pharma Mar, S.A., H2 2016
Ewing Sarcoma - Pipeline by Recombio S.L, H2 2016
Ewing Sarcoma - Pipeline by Shionogi & Co., Ltd., H2 2016
Ewing Sarcoma - Pipeline by Tesaro, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Ewing Sarcoma - Dormant Projects, H2 2016
Ewing Sarcoma - Dormant Projects (Contd..1), H2 2016
Ewing Sarcoma - Discontinued Products, H2 2016 201

LIST OF FIGURES

Number of Products under Development for Ewing Sarcoma, H2 2016
Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Soft Tissue Sarcoma - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 470 pages

Ask Your Question

Ewing Sarcoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: